Literature DB >> 14666382

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines.

Akihiro Takahashi1, Koji Kono, Fumiko Ichihara, Hidemitsu Sugai, Hideki Fujii, Yoshiro Matsumoto.   

Abstract

PURPOSE: Dendritic cells (DCs) play an important role in the host's immunosurveillance against cancer. It has been shown that the function of DCs is impaired and their population decreased in a cancer-bearing host. In the present study, we investigated the mechanism of down-regulation of DCs in a cancer-bearing host.
METHODS: We evaluated the relationship between DC infiltration and production of vascular endothelial growth factor (VEGF) in carcinoma tissue by immunohistochemistry. Furthermore, functional and phenotypical alterations of DCs were evaluated when monocyte-derived, mature DCs were treated with VEGF in vitro. Monocyte-derived DCs were generated in a culture of monocyte with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor, and the maturation of DCs was induced by either lipopolysaccharide (LPS) or a proinflammatory cytokine cocktail: tumor-necrosis factor alpha, prostaglandin E2, IL-6, and IL-1beta.
RESULTS: A significant inverse correlation was found between the density of DCs and the quantity of VEGF production in gastric carcinoma tissue (r=-0.39, p<0.05). In LPS-induced maturation, the ability of mature DCs to stimulate allogenic T cells and produce IL-12 (p70 heterodimer) was suppressed by the addition of VEGF in a dose-dependent manner. A lesser expression of costimulatory molecules (CD80 and CD86) was seen in DCs treated with exogenous VEGF than in DCs not treated with VEGF. The population of dead DCs (early and late apoptosis) treated with VEGF increased more than that without VEGF treatment, using the annexin V and propidium iodide evaluation in DCs matured by LPS. In contrast, in DCs matured by the proinflammatory cytokine cocktail, the down-regulation of costimulatory molecules and induction of DC apoptosis was not seen.
CONCLUSIONS: These findings show that the inhibition of DC maturation by VEGF differs depending on the maturation status of the DCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666382     DOI: 10.1007/s00262-003-0466-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Disruption of the transcription factor Nrf2 promotes pro-oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter.

Authors:  Marc A Williams; Tirumalai Rangasamy; Stephen M Bauer; Smruti Killedar; Matthew Karp; Thomas W Kensler; Masayuki Yamamoto; Patrick Breysse; Shyam Biswal; Steve N Georas
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

Review 3.  Dendritic cells and tumor microenvironment: a dangerous liaison.

Authors:  Ingo Fricke; Dmitry I Gabrilovich
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

Review 4.  Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

5.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

6.  Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

Authors:  Gianni Gerlini; Adrian Tun-Kyi; Christa Dudli; Günter Burg; Nicola Pimpinelli; Frank O Nestle
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 7.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

Review 8.  Deciphering and reversing tumor immune suppression.

Authors:  Greg T Motz; George Coukos
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.

Authors:  Jikui Shen; David F Choy; Tsunehiko Yoshida; Takeshi Iwase; Gulnar Hafiz; Bing Xie; Sean F Hackett; Joseph R Arron; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2014-08       Impact factor: 6.384

10.  Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation.

Authors:  Fang Liu; Zhenlin Hu; Lei Qiu; Chun Hui; Chao Li; Pei Zhong; Junping Zhang
Journal:  J Transl Med       Date:  2010-01-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.